The FDA’s September 2025 green light for a high-priced Barth syndrome drug—despite internal objections over efficacy—signals a new regulatory era where urgent need and public advocacy can override traditional scientific standards, raising profound questions about medical risk, equity, and the future of drug approval for rare diseases.
The Surface Event: What Actually Happened?
In September 2025, the U.S. Food and Drug Administration approved Stealth Biotherapeutics’ elamipretide (branded Forzinity) to treat Barth syndrome—a life-threatening condition with no prior approved therapies. At up to $800,000 annually, Forzinity’s approval is remarkable both for its cost and for the level of dissent among FDA staff scientists, who concluded the drug was “no more effective than a placebo.” Yet, after years of advocacy and mounting pressure from families, doctors, and lawmakers, the FDA’s leadership overrode these objections, citing both some minor efficacy signals and the sheer urgency faced by this ultra-rare patient group. For context: Barth syndrome affects an estimated 150 Americans, primarily male infants, causing severe cardiac failure and often early death.
Beyond the Headlines: The Fraying Boundaries of Scientific Rigor
This isn’t simply about one drug—or even about one rare disease. The FDA’s decision exposes cracks in the traditional framework that has guarded drug safety and efficacy for generations. Historically, scientific consensus—anchored in randomized, placebo-controlled clinical trials—was the gold standard for new drug approvals. But as the stories of desperate families publicized on social media and amplified by advocacy groups gain traction, the calculus for what constitutes “evidence” is evolving.
- Eight FDA reviewers recommended against Forzinity’s approval, arguing there was no “substantial evidence” of effectiveness in key studies, such as the six-minute walk test.Reuters
- The agency’s decision ultimately rested not on clear success in clinical outcomes but on “some signs of improved motor skills” and an acute unmet medical need.
The Push and Pull: The Power of Advocacy & Political Will
The Forzinity decision mirrors a larger pattern where political and emotional forces—rather than detached scientific appraisal—are increasingly shaping the FDA’s rulings on rare, so-called orphan diseases. More than 80 doctors, several lawmakers, and numerous advocacy organizations openly lobbied the agency’s leadership, arguing that inaction would be tantamount to abandoning children with no hope for treatment. Their influence was decisive. FDA lawyer Rachel Turow observed: “Internal disagreement over the adequacy of scientific evidence for ultra-rare diseases often cannot win out over patient demand for access.”The New York Times
Historical Precedent: Accelerated Approval’s Expanding Scope
The FDA’s accelerated approval pathway, created in 1992 in response to the HIV/AIDS crisis, was designed to get promising drugs to patients facing terminal illnesses with no options. Originally, its use for rare diseases was limited and required strong surrogates or post-market studies to confirm benefit.FDA.gov
But over the past decade, this standard has loosened. Notably:
- Pressure from advocacy movements—seen previously in the early approval of Exondys 51 for Duchenne muscular dystrophy (2016)—set precedent for overruling reviewer objections when faced with organized public campaigns.JAMA
- In 2024–2025, the Trump administration streamlined requirements, explicitly allowing approvals “based on one strong study and other confirmatory evidence.”
Implications: What Happens When Standards Shift?
This evolution reflects a deeply human moral conundrum: Is it more dangerous to deny hope and access for desperately ill patients, or to lower safeguards for everyone? The Forzinity case is a microcosm of broader, systemic upheaval:
- Scientific Risk: As more drugs are approved on weaker evidence, the risk of unforeseen side effects or wasted resources grows. In past accelerated approvals, drugs later failed confirmatory studies—raising fears that the system’s protective value will erode.
- Payer and Equity Challenges: Ultra-high prices—over $15,000 per week, in this case—force insurers and government programs to wager millions on therapies that may offer little benefit.Reuters This could widen inequity as coverage becomes more contested and costs shift to families or taxpayers.
- Global Precedent: The U.S. FDA is the world’s most influential regulator; its moves often set or break standards followed internationally. Countries with more conservative regimes may face increased pressure from patient groups emboldened by U.S. cases.
The Long View: Trust, Tradeoffs, and the Future of Regulation
The FDA’s willingness to prioritize urgent need and patient voice over established scientific protocol in the Forzinity case will continue to influence drug policy for years to come. For families facing dire diagnoses, new flexibility may offer a lifeline. But for the wider public—and global medical community—the risk is a drift toward regulatory relativism, where hard evidence yields to emotional and political pressure, with societal risk distributed ever more widely.
Ultimately, how we answer these dilemmas will dictate not just the lives of the rare few with Barth syndrome, but also the standards by which all future medicines are judged—and how we define the role of science in our most urgent decision-making.
